Spots Global Cancer Trial Database for recurrent uterine corpus carcinoma

Every month we try and update this database with for recurrent uterine corpus carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	NCT00063999	Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Cisplatin Doxorubicin Hyd... Filgrastim Laboratory Biom... Paclitaxel Pegfilgrastim Quality-of-Life...	18 Years -	GOG Foundation
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT00820898	Endometrial Ade... Endometrial Ade... Endometrial Cle... Recurrent Uteri...	Gemcitabine Hyd...	18 Years -	GOG Foundation
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	NCT01010126	Adult Hepatocel... Advanced Adult ... Endometrial Ser... Localized Non-R... Lung Carcinoid ... Malignant Pancr... Malignant Pancr... Malignant Pancr... Malignant Pancr... Metastatic Dige... Ovarian Carcino... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-Ce... Pancreatic Poly... Recurrent Adult... Recurrent Diges... Recurrent Fallo... Recurrent Ovari... Recurrent Pancr... Recurrent Prima... Recurrent Uteri... Regional Digest... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino...	Bevacizumab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	NCT00006089	Endometrial Ade... ERBB2 Gene Ampl... Recurrent Uteri... Stage III Uteri... Stage IV Uterin...	Laboratory Biom... Trastuzumab	18 Years -	National Cancer Institute (NCI)
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	NCT01164735	Recurrent Uteri... Stage III Uteri... Stage IV Uterin...	Laboratory Biom...	18 Years -	GOG Foundation
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery	NCT00410553	Adult Solid Neo... Recurrent Ovari... Recurrent Uteri... Stage III Ovari... Stage III Uteri... Stage IV Ovaria... Stage IV Uterin...	Eribulin Mesyla... Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	NCT01440998	Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Endometrioid Ad... Recurrent Uteri... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Dasatinib Laboratory Biom... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01225887	Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Malignant Uteri... Recurrent Uteri...	Nintedanib	18 Years -	GOG Foundation
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01642082	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Recurrent Uteri...	Dalantercept Laboratory Biom...	18 Years -	GOG Foundation
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer	NCT02684227	Recurrent Endom... Recurrent Uteri... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Enzalutamide Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	NCT00478426	Endometrial Ade... Endometrial End... Endometrial Ser... Recurrent Uteri... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino... Uterine Corpus ...	Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	NCT00064025	Endometrial Ade... Endometrial Ade... Endometrial End... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin...	Laboratory Biom... Medroxyprogeste... Therapeutic Con...	18 Years -	GOG Foundation
Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT00820898	Endometrial Ade... Endometrial Ade... Endometrial Cle... Recurrent Uteri...	Gemcitabine Hyd...	18 Years -	GOG Foundation
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT00888173	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Recurrent Uteri...	Brivanib Alanin... Laboratory Biom...	18 Years -	GOG Foundation
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
Prognostic Biomarkers in Patients With Endometrial Cancer	NCT01208467	Endometrial Ade... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin...	Laboratory Biom...	-	GOG Foundation
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer	NCT01098630	Recurrent Cervi... Recurrent Uteri... Recurrent Uteri... Stage I Uterine... Stage I Uterine... Stage IA Cervic... Stage IB Cervic... Stage II Uterin... Stage II Uterin... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Uteri... Stage III Uteri... Stage IV Uterin... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi...	Medical Chart R... Questionnaire A...	-	GOG Foundation
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer	NCT02657928	Estrogen Recept... Postmenopausal Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri...	Laboratory Biom... Letrozole Ribociclib	18 Years -	Mayo Clinic
Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies	NCT02578888	Cervical Carcin... Ovarian Carcino... Primary Periton... Recurrent Cervi... Recurrent Ovari... Recurrent Uteri... Recurrent Vulva... Uterine Corpus ... Vulvar Carcinom... Peritoneal Neop...	Palliative Ther... Palliative Ther...	-	Albert Einstein College of Medicine
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Prognostic Biomarkers in Patients With Endometrial Cancer	NCT01208467	Endometrial Ade... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin...	Laboratory Biom...	-	GOG Foundation
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer	NCT00575952	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Endometrial Squ... Endometrial Und... Recurrent Uteri... Stage IIIA Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri...	Cisplatin Doxorubicin Hyd... Filgrastim Paclitaxel Pegfilgrastim	-	GOG Foundation
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01132820	Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri...	Cediranib Malea... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	NCT00006089	Endometrial Ade... ERBB2 Gene Ampl... Recurrent Uteri... Stage III Uteri... Stage IV Uterin...	Laboratory Biom... Trastuzumab	18 Years -	National Cancer Institute (NCI)
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer	NCT01307631	Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri...	Akt Inhibitor M... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer	NCT01210222	Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Ser... Endometrioid St... Recurrent Uteri...	Trebananib	18 Years -	GOG Foundation
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer	NCT01970722	FIGO Stage IVA ... FIGO Stage IVB ... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage III Uteri... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Pegylated Lipos... Quality-of-Life... Therapeutic Con...	18 Years -	City of Hope Medical Center
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer	NCT01970722	FIGO Stage IVA ... FIGO Stage IVB ... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage III Uteri... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Pegylated Lipos... Quality-of-Life... Therapeutic Con...	18 Years -	City of Hope Medical Center
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	NCT00064025	Endometrial Ade... Endometrial Ade... Endometrial End... Recurrent Uteri... Stage I Uterine... Stage II Uterin... Stage III Uteri... Stage IV Uterin...	Laboratory Biom... Medroxyprogeste... Therapeutic Con...	18 Years -	GOG Foundation

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: